[1]祝　茜,马　倩,邸师红,等.急性中脑动脉梗死患者血清星形胶质蛋白S100B水平检测与梗死体积及预后评估的相关性研究[J].现代检验医学杂志,2021,36(02):44-48.[doi:doi:10.3969/j.issn.1671-7414.2021.02.011]
　ZHU Qian,MA Qian,DI Shi-hong,et al.Correlation between the Detection of Serum Astrocyte S100B Level and the Infarct Volume and Prognosis in Patients with Acute Middle Cerebral Artery Infarction[J].Journal of Modern Laboratory Medicine,2021,36(02):44-48.[doi:doi:10.3969/j.issn.1671-7414.2021.02.011]
点击复制

急性中脑动脉梗死患者血清星形胶质蛋白S100B水平检测与梗死体积及预后评估的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年02期
页码:
44-48
栏目:
论　著
出版日期:
2021-04-30

文章信息/Info

Title:
Correlation between the Detection of Serum Astrocyte S100B Level and the Infarct Volume and Prognosis in Patients with Acute Middle Cerebral Artery Infarction
文章编号:
1671-7414（2021）02-044-05
作者:
祝　茜; 马　倩; 邸师红; 等
（宁夏医科大学总医院心脑血管病医院医学检验科，银川 750001）
Author(s):
ZHU Qian;  MA Qian;  DI Shi-hong;  et al
（Department of Clinical Laboratory, Hospital of Cardiovascular and Cerebrovascular Diseases, General Hospital of Ningxia Medical University, Yinchuan 750001, China）
关键词:
血清星形胶质蛋白; 急性中脑动脉梗死; 预后评估; 梗死体积
分类号:
R743.3；R446.112
DOI:
doi:10.3969/j.issn.1671-7414.2021.02.011
文献标志码:
A
摘要:
目的　探讨血清星形胶质蛋白（S100B）水平在急性中脑动脉梗死患者的梗死体积和预后评估中的临床应用价值。方法　选取39例于2019年1月~2020年1月在宁夏医科大学总医院心脑血管病医院神经内科就诊的急性非腔隙中脑动脉梗死患者作为研究对象，并从正常人群中随机抽取40例健康体检者作为对照组。采用免疫荧光法检测患者入院时（0h）和症状发作后24，48，72，96，120和144 h的血清S100B水平，采用改良的Rankin量表评估患者预后情况，使用磁共振成像或计算机断层扫描确定第7天的最终梗死体积。观察对照组、疾病组和疾病组内不同时间点的血清S100B水平与急性中脑动脉梗死疾病之间的关系。结果　与对照组相比，患者入院时的S100B血清浓度范围为0.12±0.07 μg/L。S100B AUC的范围为196.5±267.5 μg/ L·h。血清S100B浓度与mRS得分之间具有高度相关性，差异具有统计学意义（P＜0.01)。Spearman相关性分析表明48 h和72 h的S100B检测结果与预后评估（ρ= 0.68，ρ= 0.67）以及梗死体积（ρ = 0.95， 0.94）的相关性最高，差异具有统计学意义（P < 0.001）。当48 h的血清S100B浓度≤ 0.37 μg/L时，血清S100B的独立预测功能的灵敏度为0.87，特异度为0.78，差异具有统计学意义（P＜0.01)。在包括年龄、性别、病灶、NIHHSS评分、血管危险因素和卒中病因的多元逐步逻辑回归模型中，S100B是一种独立的结果预测指标（P＜0.01）。单变量线性回归分析表明S100B值与最终梗死体积具有显著相关性，差异具有统计学意义（P＜0.01)。结论　血清S100B是预测急性中脑动脉梗死患者的功能结局和梗死体积的良好指标和实验室检测手段。

参考文献/References:

[1] ABE A, OTA T, UEDA M, et al. Tokyo metropolitan stroke emergency medical services for interventional stroke treatment: the Tama-REgistry of acute thrombectomy (TREAT) study[J]. Journal of Stroke and Cerebrovascular Diseases, 2020, 29(6): 104752.
[2] 樊春荔, 何燕娟.缺血性脑卒中和短暂性脑缺血发作患者血清miR-23b-3p水平变化的比较研究[J].现代检验医学杂志, 2020, 35(5):51-54, 123. FAN Chunli，HE Yanjuan. Altered levels of serum miR-23b-3p in patients with ischemic stroke and transient ischemic attack [J]. Journal of Modern Laboratory Medicine,2020,35(5):51-54,123.
[3] 郭凯.MR弥散加权成像与CT灌注在急性缺血性脑卒中诊断中的应用价值[J].现代医药卫生, 2020, 36(9):1377-1379. GUO Kai. The value of MR diffusion weighted imaging and CT perfusion in the diagnosis of acute ischemic stroke[J].Journal of Modern Medicine & Health， 2020,36(9):1377-1379.
[4] 高宏娥,李荫桂,黄海云,等.缺血性脑卒中患者血浆脂蛋白相关磷脂酶 A2测定的临床意义[J]．现代检验医学杂志,2015,30(2):58-60,64. GAO Honge, LI Yingui, HUANG Haiyun, et al. Clinical significance of plasma lipoprotein-associated phospholipase A2 detecting in patients with ischemic cerebral stroke [J]. Journal of Modern Laboratory Medicine, 2015,30(2):58-60,64.
[5] KIM J S, YOON S S, KIM Y H, et al. Serial Measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke[J]. Stroke,. 1996, 27(9):1553-1557.
[6] 邓凯,许薇,李燕.缺血性脑卒中患者血浆vWF:Ag和S100B检测的临床意义[J].现代检验医学杂志, 2017, 32(5):52-54, 58. DENG Kai, XU Wei, LI Yan. Clinical application of detection of plasma vWF:Ag and S100B in ischemic cerebral apoplexy disease[J]. Journal of Modern Laboratory Medicine,2017,32(5):52-54,58.
[7] LIU Yidong, MYRVANG H K, DEKKER L V. Annexin A2 complexes with S100 proteins: structure, function and pharmacological manipulation [J]. British Journal of Pharmacology, 2015, 172(7):1664-1676.
[8] WANG Jiaan, WU Xicai, TIAN Yufeng, et al. Dynamic changes and diagnostic and prognostic significance of serum PCT, hs-CRP and S-100 protein in central nervous system infection[J].Experimental and Therapeutic Medicine, 2018, 16(6): 5156-5160.
[9] MAKOVEC M, KERIN K, SKITEK M, et al. Association of biomarker S100B and cerebral oximetry with neurological changes during carotid endarterectomy performed in awake patients[J]. VASA -Zeitschrift für Gef.sskrankheiten. Journal for Vascular Diseases, 2020, 49(1):1-9.
[10] MOSS B P, PATEL D C, TAVEE J O, et al. Evaluating S100B as a serum biomarker for central neurosarcoidosis[J]. Respiratory Medicine, 2020,162:105855.
[11] JONES C, HARMON C, MCCANN M, et al. S100B outperforms clinical decision rules for the identification of intracranial injury on head CT scan after mild traumatic brain injury[J]. Brain Injury, 2020, 34(3): 407-414.
[12] LU Yulan,WANG Rong,HUANG Huatuo,et al. Association of S100B polymorphisms and serum S100B with risk of ischemic stroke in a Chinese population [J]. Scientific Reports, 2018, 8(1): 495-506.
[13] ZHANG Jinhua, LI Jiangkun, MA Lili, et al. RNA interference-mediated silencing of S100B improves nerve function recovery and inhibits hippocampal cell apoptosis in rat models of ischemic stroke [J]. Journal of Cellular Biochemistry, 2018, 119(10): 8095-8111.
[14] BEAUDEUX J L, LARIBI S. S100B protein serum level as a biomarker of minor head injury[J]. Annales de Biologie Clinique, 2013, 71(1): 71-78.
[15] ASTRAND R, UNDéN J. Clinical use of the Calcium-Binding S100B protein, a biomarker for head injury[J]. Methods in Molecular Biology (Clifton, N.J.), 2019, 1929: 679-690.
[16] 朱娜,陈博,张小艳,等.血清S100-β蛋白对闭合性颅脑损伤患者诊断及预后临床价值的研究[J].现代检验医学杂志, 2017,32(5):59-61. ZHU Na, CHEN Bo, ZHANG Xiaoyan, et al. Clinical value of serum S100-beta protein in the diagnosis and prognosis of patients with closed craniocerebral injury [J]. Journal of Modern Laboratory Medicine, 2017,32(5):59-61.

备注/Memo

备注/Memo:
基金项目：宁夏医科大学校级课题（项目编号：XY2017193）。
作者简介：祝茜（1986-），女，本科学历，主管检验技师，研究方向为免疫学检验，E-mail: 527504941@qq.com。
通讯作者：李占君，E-mail：LZJ1124@163.com。
更新日期/Last Update: 2021-04-10